United Therapeutics

UTHR

Market cap $21.7B

United Therapeutics Corp (NASDAQ: UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.

United Therapeutics Corporation delivered strong Q4 and FY2025 results, with revenues up 10%+ and net income per share up ~14%, driving a >75% stock rally. UTHR's Tyvaso remains the dominant PAH franchise, with robust growth and new product innovations like Tresmi and ralinepag poised to reinforce market leadership. Major data catalysts in PAH (ralinepag Phase 3) and IPF (TETON-1/2) could unlock billion-dollar opportunities and further accelerate UTHR's revenue trajectory.

United Therapeutics Q4 earnings beat estimates, Tyvaso DPI sales jump 24% despite revenue miss.

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

United Therapeutics (UTHR) came out with quarterly earnings of $7.7 per share, beating the Zacks Consensus Estimate of $6.78 per share. This compares to earnings of $6.19 per share a year ago.

United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. “As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation.

Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An arch.

Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.